ClinicalTrials.gg

Program

BNT166A

A development code. Also written as “BNT166a”.

Its studies are mostly in Mpox, Monkeypox, led by BioNTech.

Furthest: phase 2, since Aug 4, 20232 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTech21 open or runningphase 2since Aug 4, 2023Aug 4, 2023Jun 2027phase 2 · NCT07379580

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2023First study: phase 2 study in Mpox, MonkeypoxFirst studyNCT05988203 · 96 enrolled · United States, United Kingdom
  2. Jan 23, 2026Phase 2 study in Mpox, MonkeypoxNCT07379580 · 310 planned · Democratic Republic of the Congo, South Africa

Ahead

  1. Jun 2027Primary completion: phase 2 study in Mpox, MonkeypoxNCT07379580

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07379580Mpox, Monkeypox · Democratic Republic of the Congo, South Africa2RecruitingJun 2027310
NCT05988203Mpox, Monkeypox · United States, United Kingdom2CompletedAug 25, 202596

How it is read

Names in the registry

  • “BNT166a”, 2 entries

Codes read as this program: BNT166A.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.